CR20110556A - Proteinas de fusion rage y metodos de empleo - Google Patents

Proteinas de fusion rage y metodos de empleo

Info

Publication number
CR20110556A
CR20110556A CR20110556A CR20110556A CR20110556A CR 20110556 A CR20110556 A CR 20110556A CR 20110556 A CR20110556 A CR 20110556A CR 20110556 A CR20110556 A CR 20110556A CR 20110556 A CR20110556 A CR 20110556A
Authority
CR
Costa Rica
Prior art keywords
fusion proteins
rage fusion
rage
employment methods
methods
Prior art date
Application number
CR20110556A
Other languages
English (en)
Inventor
Adnan M M Mjalli
Ye E Tian
Jeffrey C Webster
Robert Rothlein
Original Assignee
Transtech Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transtech Pharma Inc filed Critical Transtech Pharma Inc
Publication of CR20110556A publication Critical patent/CR20110556A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

La presente invención trata acerca de la regulación del receptor de productos avanzados de glicosilación (RAGE por sus siglas en inglés). Más particularmente, la presente invención describe proteínas de fusión que incluyen a un polipéptido RAGE, métodos para preparar dichas proteína de fusión y el uso de dichas protéinas para el tratamiento de trastornos relacionados con el RAGE.
CR20110556A 2004-08-03 2011-10-20 Proteinas de fusion rage y metodos de empleo CR20110556A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US59855504P 2004-08-03 2004-08-03

Publications (1)

Publication Number Publication Date
CR20110556A true CR20110556A (es) 2011-11-10

Family

ID=35149359

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20110556A CR20110556A (es) 2004-08-03 2011-10-20 Proteinas de fusion rage y metodos de empleo

Country Status (23)

Country Link
US (5) US7901688B2 (es)
EP (1) EP1781700B1 (es)
JP (1) JP5188804B2 (es)
KR (1) KR101323411B1 (es)
CN (1) CN1993378A (es)
AP (1) AP2007003869A0 (es)
AU (1) AU2005271452B2 (es)
BR (1) BRPI0514052A (es)
CA (1) CA2570324C (es)
CR (1) CR20110556A (es)
EA (1) EA012082B1 (es)
EC (1) ECSP077221A (es)
ES (1) ES2473587T3 (es)
GE (1) GEP20105110B (es)
IL (1) IL180554A (es)
MA (1) MA29067B1 (es)
MX (1) MX2007001559A (es)
NO (1) NO20065949L (es)
NZ (1) NZ552128A (es)
TN (1) TNSN07037A1 (es)
UA (1) UA93356C2 (es)
WO (1) WO2006017647A1 (es)
ZA (2) ZA200700643B (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465422B1 (en) * 1998-04-17 2002-10-15 The Trustees Of Columbia University In The City Of New York Method for inhibiting tumor invasion or spreading in a subject
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
US7696169B2 (en) * 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
JP4792392B2 (ja) * 2003-09-11 2011-10-12 コーナーストーン セラピューティクス インコーポレイテッド Ｈｍｇｂ１に対するモノクローナル抗体
US20090060925A1 (en) * 2004-08-03 2009-03-05 The Trustees Of Columbia University In The City Of Rage Fusion Proteins and Methods of Use
CA2570324C (en) * 2004-08-03 2014-07-22 Transtech Pharma, Inc. Rage fusion proteins and methods of use
WO2006119510A2 (en) * 2005-05-04 2006-11-09 Receptor Biologix, Inc. Isoforms of receptor for advanced glycation end products (rage) and methods of identifying and using same
US20080311122A1 (en) * 2005-11-28 2008-12-18 Medimmune, Llc Antagonists of Hmgb1 and/or Rage and Methods of Use Thereof
EP1963786B1 (en) * 2005-12-23 2013-07-24 GCoder Systems AB Positioning pattern
WO2007094926A2 (en) * 2006-02-09 2007-08-23 Transtech Pharma, Inc. Rage fusion proteins and methods of use
SG171670A1 (en) * 2006-05-05 2011-06-29 Transtech Pharma Inc Rage fusion proteins, formulations, and methods of use thereof
CA2963138C (en) 2007-01-30 2019-05-14 Epivax, Inc. Regulatory t cell epitopes, compositions and uses thereof
WO2008100470A2 (en) * 2007-02-15 2008-08-21 Transtech Pharma, Inc. Rage - immunoglobulin fusion proteins
US20100254983A1 (en) * 2007-06-07 2010-10-07 Ann Marie Schmidt Uses of rage antagonists for treating obesity and related diseases
CN101842382A (zh) * 2007-06-14 2010-09-22 卡拉狄加制药公司 Rage融合蛋白
WO2009054435A1 (ja) * 2007-10-24 2009-04-30 Otsuka Chemical Co., Ltd. 増強されたエフェクター機能を有するポリペプチド
NL2001552C2 (nl) * 2008-05-06 2009-05-07 Transtech Pharma Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001555C2 (nl) * 2008-05-06 2009-05-07 Transtech Pharma Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001553C2 (nl) * 2008-05-06 2009-05-07 Transtech Pharma Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001556C2 (nl) * 2008-05-06 2009-05-07 Transtech Pharma Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001557C2 (nl) * 2008-05-06 2009-05-07 Transtech Pharma Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001554C2 (nl) * 2008-05-06 2009-05-07 Transtech Pharma Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001551C2 (nl) * 2008-05-06 2009-05-07 Transtech Pharma Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001558C2 (nl) * 2008-05-06 2009-05-07 Transtech Pharma Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
US20110105961A1 (en) 2008-05-23 2011-05-05 Gruber Lewis S Methods, compositions and apparatuses for facilitating regeneration
EP2421892A1 (en) 2009-04-20 2012-02-29 Pfizer Inc. Control of protein glycosylation and compositions and methods relating thereto
WO2011100508A2 (en) * 2010-02-12 2011-08-18 Arizona Board Of Regents For And On Behalf Of Arizona State University Methods and compositions related to glycoprotein-immunoglobulin fusions
WO2011102845A1 (en) * 2010-02-18 2011-08-25 Transtech Pharma, Inc. Rage fusion protein compositions and methods of use
ES2725852T3 (es) 2010-09-27 2019-09-27 Siwa Corp Eliminación selectiva de células modificadas por AGE para el tratamiento de la aterosclerosis
US8721571B2 (en) 2010-11-22 2014-05-13 Siwa Corporation Selective removal of cells having accumulated agents
IL312872A (en) 2011-06-28 2024-07-01 Inhibrx Inc Methods for purifying fusion proteins containing serphin
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
MX356433B (es) 2011-06-28 2018-05-29 Inhibrx Lp Polipéptidos de fusión con domino de proteína ácida del suero, y métodos de uso de los mismos.
CN104736558A (zh) * 2012-09-07 2015-06-24 赛诺菲 用于治疗代谢综合征的融合蛋白
WO2015023165A1 (ko) * 2013-08-16 2015-02-19 가톨릭대학교 산학협력단 염증조절복합체 및 ｓｔａｔ３ 신호분자 차단을 통한 면역조절능 최적화된 안정화 중간엽줄기세포
ES2908203T3 (es) * 2014-09-19 2022-04-28 Siwa Corp Anticuerpos anti-age para el tratamiento de inflamación y trastornos autoinmunes
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
RU2728964C2 (ru) 2016-02-19 2020-08-03 Сива Корпорейшн Способ и композиция для лечения рака, уничтожения метастатических раковых клеток и профилактики метастазов рака, используя антитела к конечным продуктам повышенного гликирования ( AGE)
CN109311975A (zh) 2016-04-15 2019-02-05 Siwa有限公司 用于治疗神经退行性紊乱的抗age抗体
CN115304669A (zh) * 2016-06-08 2022-11-08 上海交通大学医学院 增强激动型抗体活性的抗体重链恒定区序列
US11213585B2 (en) 2016-06-23 2022-01-04 Siwa Corporation Vaccines for use in treating various diseases and disorders
US10925937B1 (en) 2017-01-06 2021-02-23 Siwa Corporation Vaccines for use in treating juvenile disorders associated with inflammation
US10995151B1 (en) 2017-01-06 2021-05-04 Siwa Corporation Methods and compositions for treating disease-related cachexia
US10858449B1 (en) 2017-01-06 2020-12-08 Siwa Corporation Methods and compositions for treating osteoarthritis
US10961321B1 (en) 2017-01-06 2021-03-30 Siwa Corporation Methods and compositions for treating pain associated with inflammation
EP3583119A2 (en) * 2017-02-17 2019-12-25 Denali Therapeutics Inc. Engineered polypeptides
US10457717B2 (en) 2017-02-17 2019-10-29 Denali Therapeutics Inc. Engineered polypeptides
US10143187B2 (en) 2017-02-17 2018-12-04 Denali Therapeutics Inc. Transferrin receptor transgenic models
CA3059803A1 (en) 2017-04-13 2018-10-18 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
WO2020056379A1 (en) 2018-09-14 2020-03-19 BioAge Labs, Inc. Rage fusion proteins with improved stability and ligand binding affinity and uses thereof

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4867973A (en) * 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US6018026A (en) * 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
US5567584A (en) * 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
NZ235148A (en) * 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
MX9204374A (es) * 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
SE9201073D0 (sv) * 1992-04-03 1992-04-03 Kabi Pharmacia Ab Protein formulation
PT672141E (pt) 1992-10-23 2003-09-30 Immunex Corp Metodos de preparacao de proteinas oligomericas soluveis
NO315930B1 (no) * 1995-01-18 2003-11-17 Picower Inst For Medical Res T Anvendelse av tiazoliumforbindelser ved fremstilling av farmasöytiske preparater, preparater som inneholder forbindelsene, samt nyetiazoliumforbindelser
US5656261A (en) * 1995-01-18 1997-08-12 The Picower Institute For Medical Research Preventing and reversing advanced glycosylation endproducts
MX9705449A (es) * 1995-01-18 1998-02-28 Alteon Inc Uso de compuestos de tiazolio para evitar y revertir la formacion de productos finales de glicosilacion avanzada.
JPH11504316A (ja) * 1995-04-05 1999-04-20 ザ ピコワー インスティテュート フォア メディカル リサーチ 進行性グリコシル化終末産物に結合する薬剤及びその使用方法
US5747035A (en) * 1995-04-14 1998-05-05 Genentech, Inc. Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
WO1997026913A1 (en) 1996-01-26 1997-07-31 The Trustees Of Columbia University In The City Of New York A POLYPEPTIDE FROM LUNG EXTRACT WHICH BINDS AMYLOID-β PEPTIDE
AU2696097A (en) 1996-04-16 1997-11-07 Schering Aktiengesellschaft Advanced glycosylation end-product receptor peptides and uses therefor
US5864018A (en) * 1996-04-16 1999-01-26 Schering Aktiengesellschaft Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor
US7258857B2 (en) * 1996-11-22 2007-08-21 The Trustees Of Columbia University In The City Of New York Rage-related methods for treating inflammation
US6790443B2 (en) * 1996-11-22 2004-09-14 The Trustees Of Columbia University In The City Of New York Method for treating symptoms of diabetes
US7081241B1 (en) * 1998-10-06 2006-07-25 The Trustees Of Columbia University In The City Of New York Extracellular rage binding protein (EN-RAGE) and uses thereof
US6555651B2 (en) * 1997-10-09 2003-04-29 The Trustees Of Columbia University In The City Of New York Ligand binding site of rage and uses thereof
WO1998040071A1 (en) 1997-03-11 1998-09-17 The General Hospital Corporation Identification of agents for use in the treatment of alzheimer's disease
US6165476A (en) 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
US7101838B2 (en) * 1997-08-05 2006-09-05 The Trustees Of Columbia University In The City Of New York Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts
ZA988461B (en) 1997-09-18 1999-03-30 Idec Pharma Corp Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis
US6380165B1 (en) * 1997-09-19 2002-04-30 The Picower Institute For Medical Research Immunological advanced glycation endproduct crosslink
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6323218B1 (en) 1998-03-11 2001-11-27 The General Hospital Corporation Agents for use in the treatment of Alzheimer's disease
US6465422B1 (en) 1998-04-17 2002-10-15 The Trustees Of Columbia University In The City Of New York Method for inhibiting tumor invasion or spreading in a subject
WO2000018970A1 (fr) 1998-09-29 2000-04-06 Asahi Kasei Kabushiki Kaisha Procede de commande de liberation de granules
US6753150B2 (en) * 1998-10-05 2004-06-22 The Trustees Of Columbia University In The City Of New York Method for determining whether a compound is capable of inhibiting the interaction of a peptide with rage
AU765719B2 (en) 1998-10-06 2003-09-25 Trustees Of Columbia University In The City Of New York, The Extracellular novel rage binding protein (EN-RAGE) and uses thereof
US6197294B1 (en) * 1998-10-26 2001-03-06 Neurotech S.A. Cell surface molecule-induced macrophage activation
US6605642B2 (en) * 1999-04-05 2003-08-12 City Of Hope Inhibitors of formation of advanced glycation endproducts (AGES)
US6787566B2 (en) * 1999-04-05 2004-09-07 City Of Hope Breakers of advanced glycation endproducts
US6589944B1 (en) 1999-04-05 2003-07-08 City Of Hope Breakers of advanced glycation endproducts
US6939545B2 (en) * 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
US6835200B2 (en) 1999-06-22 2004-12-28 Ndo Surgical. Inc. Method and devices for tissue reconfiguration
FR2797402B1 (fr) 1999-07-15 2004-03-12 Biomerieux Stelhys Utilisation d'un polypeptide pour detecter, prevenir ou traiter un etat pathologique associe a une maladie degenerative, neurologique ou autoimmune
WO2001012598A2 (en) 1999-08-13 2001-02-22 The Trustees Of Columbia University In The City Of New York METHODS OF INHIBITING BINDING OF β-SHEET FIBRIL TO RAGE AND CONSEQUENCES THEREOF
EP1219639A4 (en) 1999-09-08 2009-03-25 Toray Industries CIPO - Patent
US20050170382A1 (en) * 1999-10-06 2005-08-04 The Trustees Of Columbia University In The City Of New York. RAGE-related compositions
WO2001029269A2 (en) 1999-10-21 2001-04-26 Case Western Reserve University Gene expression profiling of inflammatory bowel disease
CA2382165A1 (en) * 1999-12-08 2001-06-14 Genset S.A. Full-length human cdnas encoding potentially secreted proteins
US6727353B2 (en) * 2000-04-14 2004-04-27 Icagen, Inc. Nucleic acid encoding Kv10.1, a voltage-gated potassium channel from human brain
DE60129008T2 (de) * 2000-04-14 2007-10-11 Niadyne Corp., Tucson Methode zur identifizierung von regulatoren der bildung von protein-age-derivaten
AU2001255436A1 (en) 2000-04-17 2001-10-30 Transtech Pharma Protein expression system arrays and use in biological screening
WO2001086002A2 (en) 2000-05-09 2001-11-15 Genetics Institute, Llc Compositions, kits, and methods for identification, assessment, prevention, and therapy of psoriasis
US6908741B1 (en) 2000-05-30 2005-06-21 Transtech Pharma, Inc. Methods to identify compounds that modulate RAGE
US6613801B2 (en) 2000-05-30 2003-09-02 Transtech Pharma, Inc. Method for the synthesis of compounds of formula I and their uses thereof
JP2004519090A (ja) * 2000-08-07 2004-06-24 アンバーウェーブ システムズ コーポレイション 歪み表面チャネル及び歪み埋め込みチャネルｍｏｓｆｅｔ素子のゲート技術
US6825164B1 (en) * 2000-08-14 2004-11-30 The Trustees Of Columbia University In The City Of New York Method to increase cerebral blood flow in amyloid angiopathy
US6563015B1 (en) 2000-08-14 2003-05-13 The Trustees Of Columbia University In The City Of New York Transgenic mice over-expressing receptor for advanced glycation endproduct (RAGE) and mutant APP in brain and uses thereof
PL366009A1 (en) * 2000-10-02 2005-01-24 Reddy Us Therapeutics, Inc. Methods and compositions for the treatment of inflammatory diseases
WO2002030889A2 (en) * 2000-10-13 2002-04-18 The Trustees Of Columbia University In The City Of New York A method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury
US20050244849A1 (en) * 2000-12-15 2005-11-03 Genetics Institute, Llc Screening assays for rheumatoid arthritis
HUP0600450A2 (en) 2000-12-29 2006-09-28 Reddy Us Therapeutics Detection of compounds that modulate inflammatory responses
US6946277B2 (en) 2001-01-31 2005-09-20 Council Of Scientific And Industrial Research Method for enhancing cellobiase activity of termitomyces clypeatus using a glycosylation inhibitor
WO2002066514A2 (en) * 2001-02-19 2002-08-29 Merck Patent Gmbh Artificial fusion proteins with reduced immunogenicity
DE10164805B4 (de) 2001-02-28 2011-02-10 Koch-Pelster, Brigitte, Dr. Verfahren und Mittel zur Modifikation humaner Angiogenese
JP3837494B2 (ja) * 2001-03-19 2006-10-25 国立大学法人金沢大学 可溶型ｒａｇｅタンパク質
PT1370571E (pt) * 2001-03-22 2005-09-30 Vlaams Interuniv Inst Biotech Processos e aparelhos para analises qualitativas e quantitativas, isentas de gel, do proteoma e as suas utilizacoes
US7304034B2 (en) * 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
AU2004236174B2 (en) 2001-10-10 2011-06-02 Novo Nordisk A/S Glycopegylation methods and proteins/peptides produced by the methods
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
JP2006506442A (ja) 2002-07-09 2006-02-23 ポイント セラピューティクス， インコーポレイテッド ボロプロリン化合物併用療法
CA2495663A1 (en) * 2002-08-16 2004-02-26 Wyeth Compositions and methods for treating rage-associated disorders
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
WO2004055055A1 (en) 2002-12-13 2004-07-01 Licentia Ltd The transmembrane protein amigo and uses thereof
US8067371B2 (en) * 2003-05-09 2011-11-29 The Trustees Of Columbia University In The City Of New York RAGE G82S-related methods and compositions for treating inflammatory disorders
WO2005000295A1 (en) * 2003-05-20 2005-01-06 Transtech Pharma, Inc. Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
WO2005021710A2 (en) * 2003-06-02 2005-03-10 University Of Miami Chimeric molecules and methods of use
WO2005019429A2 (en) 2003-08-22 2005-03-03 Potentia Pharmaceuticals, Inc. Compositions and methods for enhancing phagocytosis or phagocyte activity
US20070014791A1 (en) * 2003-09-05 2007-01-18 Schmidt Ann M Rage-related methods and copositions for treating glomerular injury
US20070167360A1 (en) * 2003-10-31 2007-07-19 Yan Shi D Methods for treating multiple sclerosis
WO2005049852A2 (en) 2003-11-17 2005-06-02 University Of Florida Methods and compositions for inducing apoptosis
WO2005051995A2 (en) 2003-11-19 2005-06-09 Curagen Corporation Novel advanced glycosylation end product-specific receptor-like protein and nucleic acids encoding same
GB0330079D0 (en) 2003-12-20 2004-02-04 Bioinvent Int Ab Vaccine
CN100342017C (zh) 2004-05-10 2007-10-10 中国医学科学院肿瘤医院肿瘤研究所 基因重组趋化抗原疫苗
JP2008504335A (ja) 2004-07-02 2008-02-14 クレアビリス・セラピューティクス・エスピーエー Ｈｍｇｂ１に関連する病変の治療のための核酸
US20060012414A1 (en) * 2004-07-15 2006-01-19 Texas Instruments Incorporated Circuit and method for generating a polyphase clock signal and system incorporating the same
WO2006012373A2 (en) 2004-07-20 2006-02-02 Critical Therapeutics, Inc. Combination therapies of hmgb and complement inhibitors against inflammation
WO2006012415A2 (en) 2004-07-20 2006-02-02 Critical Therapeutics, Inc. Rage protein derivatives
US20090060925A1 (en) * 2004-08-03 2009-03-05 The Trustees Of Columbia University In The City Of Rage Fusion Proteins and Methods of Use
CA2570324C (en) * 2004-08-03 2014-07-22 Transtech Pharma, Inc. Rage fusion proteins and methods of use
AU2005289594B2 (en) 2004-09-27 2012-02-02 Centocor, Inc. Srage mimetibody, compositions, methods and uses
WO2006119510A2 (en) 2005-05-04 2006-11-09 Receptor Biologix, Inc. Isoforms of receptor for advanced glycation end products (rage) and methods of identifying and using same
US20080207499A1 (en) * 2005-06-29 2008-08-28 Gaetano Barile Rage-related methods for treating and preventing diabetic retinopathy
WO2007094926A2 (en) * 2006-02-09 2007-08-23 Transtech Pharma, Inc. Rage fusion proteins and methods of use
SG171670A1 (en) * 2006-05-05 2011-06-29 Transtech Pharma Inc Rage fusion proteins, formulations, and methods of use thereof
EP2395077A1 (en) 2006-11-03 2011-12-14 Wyeth LLC Glycolysis-inhibiting substances in cell culture
WO2008100470A2 (en) 2007-02-15 2008-08-21 Transtech Pharma, Inc. Rage - immunoglobulin fusion proteins
CN101842382A (zh) 2007-06-14 2010-09-22 卡拉狄加制药公司 Rage融合蛋白

Also Published As

Publication number Publication date
US7981423B2 (en) 2011-07-19
GEP20105110B (en) 2010-11-10
CN1993378A (zh) 2007-07-04
KR101323411B1 (ko) 2013-10-30
NZ552128A (en) 2009-09-25
ZA200906459B (en) 2010-05-26
US20110244516A1 (en) 2011-10-06
NO20065949L (no) 2007-01-16
UA93356C2 (ru) 2011-02-10
IL180554A (en) 2013-09-30
AU2005271452A1 (en) 2006-02-16
EP1781700B1 (en) 2014-03-19
ZA200700643B (en) 2010-07-28
US8877192B2 (en) 2014-11-04
US20120171202A1 (en) 2012-07-05
US20080075733A1 (en) 2008-03-27
AP2007003869A0 (en) 2007-02-28
WO2006017647A1 (en) 2006-02-16
EP1781700A1 (en) 2007-05-09
MX2007001559A (es) 2007-04-10
KR20070039981A (ko) 2007-04-13
MA29067B1 (fr) 2007-12-03
EA012082B1 (ru) 2009-08-28
JP2008512988A (ja) 2008-05-01
ECSP077221A (es) 2007-03-29
ES2473587T3 (es) 2014-07-07
CA2570324C (en) 2014-07-22
US20060030527A1 (en) 2006-02-09
IL180554A0 (en) 2007-06-03
EA200700404A1 (ru) 2007-06-29
US20110124102A1 (en) 2011-05-26
US7901688B2 (en) 2011-03-08
BRPI0514052A (pt) 2008-05-27
AU2005271452B2 (en) 2011-11-03
JP5188804B2 (ja) 2013-04-24
CA2570324A1 (en) 2006-02-16
TNSN07037A1 (fr) 2008-06-02

Similar Documents

Publication Publication Date Title
CR20110556A (es) Proteinas de fusion rage y metodos de empleo
NL301089I2 (nl) imlifidase
ECSP20081591A (es) Proteínas de fusión que comprenden progranulina
BR112018014671A2 (pt) moléculas que ativam seletivamente células t reguladoras para o tratamento das doenças autoimunes
CO2019002609A2 (es) Proteínas de unión recombinantes y sus usos
ECSP099833A (es) Anticuerpos humanizados contra el globulomero a?(20-42) y sus usos
GT201200189A (es) Antagonistas de pcsk9
UY29282A1 (es) Anticuerpos humanizados que reconocen el peptido beta amiloideo
CL2021000909A1 (es) Anticuerpos estabilizadores de trem2
AR048912A1 (es) Inmunoglobulinas anti-nogo
PE20091193A1 (es) Proteinas humanas de union a antigenos del gm-csf
PE20211272A1 (es) POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO
MX2009013194A (es) Proteinas de fusion del receptor para productos finales de glicacion avanzada.
BRPI0515649B8 (pt) Processo para preparação de composições de anticorpo monoclonal altamente concentradas
SV2010003494A (es) Anticuerpos anti-cxcr5 humanizados, derivados de los mismos y su uso
CO6251325A2 (es) Un anticuerpo humano o humanizado, o un fragmento del mismo con una region de enlace de antigeno que es especifica para dirigir la proteina al receptor de limfoproteina estromal timica humana (htslpr)
AR053252A1 (es) Antiuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
ES2530777T3 (es) Vacunas peptídicas para cánceres que expresan antígenos asociados a tumores
WO2018115432A3 (en) COMPOUNDS FOR THE TREATMENT OF BOVINE OR PORCINE RESPIRATORY DISEASE
CR8167A (es) Procedimiento para la preparacion de derivados de espirobenzoacepina sustituida no peptidica
CL2007002380A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento terapeutico y/o profilactico de la queratosis actinica.
BR112017017609A2 (pt) proteína de fusão fc, e, composição farmacêutica.
NO20082345L (no) Selektive VPAC2 reseptorpeptidagonister
DE602006013462D1 (de) Besonders zur festlegung von sitzpositionen ausgeführte befestigungssysteme
CO2021009129A2 (es) Tubulisinas y conjugados de proteína-tubulisina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)